Proteinuria (protein in urine) is common with complement 3 glomeropathy and is a strong predictor of disease progression and end-stage kidney failure.

Mirum Pharmaceuticals, Inc. , a leading rare disease company, today provided its preliminary and unaudited estimates for full-year 2025 net product sales, year-end cash balance, corporate updates and ...

At every election—general or presidential—we do not truly vote, we simply outvote. We push out the incumbent and bring in ...

U.S. commercial launch in thalassemia underway following December 2025 FDA approvalPre-sNDA meeting with FDA for mitapivat in sickle cell disease anticipated in first quarter of 2026, with planned U.S ...

Sinai Health researchers have shown a blood test that can predict Crohn's disease years before symptoms appear, opening the ...

Ozempic may be more expensive and harder to find now that compounded semaglutide isn’t available. Here are seven reputable ...